Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001276750-25-000004
Filing Date
2025-10-31
Accepted
2025-10-31 16:41:55
Documents
1
Period of Report
2025-10-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1761943312.html 4  
1 FORM 4 wk-form4_1761943312.xml 4 4197
  Complete submission text file 0001276750-25-000004.txt   5785
Mailing Address C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134
Business Address
KIRSKE DAVID (Reporting) CIK: 0001276750 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38295 | Film No.: 251441124

Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Issuer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)